SMARTER INSIGHTS, FASTER CURESTM

We translate big-data into breakthrough cancer therapies.

BE THE innovatiON

WE BELIEVE THAT INNOVATING CANCER DRUG DEVELOPMENT REQUIRES DEEPER MECHANISTIC INSIGHTS INTO CANCER BIOLOGY, AND THAT REQUIRES THE EXPONENTIAL POWER OF ARTIFICIAL INTELLIGENCE.

Equipped with advanced cognitive computing technologies, we are able to aggregate and mine disparate types of biomedical datasets to reveal novel contextual vulnerabilities in cancer, and collaborate with leading universities to exploit those vulnerabilities with cutting-edge agents.

We then invest in the most promising experimental agents to demonstrate their therapeutic potential. Finally, we partner with pharmaceutical companies to transform innovative new agents into the breakthrough cancer therapies.

CORE VALUES

IMAGINATION

INNOVATION

INTEGRITY

OUR UNIQUE PROCESS

Our approach to cancer research is revolutionary. Applying the exponential power of our cognitive computing platform and a unique multi-scalar systems modeling approach, our team of scientists are able to extract much deeper insights into the molecular contexts that represent the best therapeutic vulnerabilities in cancer. Modeling multi-dimensional disease mechanisms is critical to our ability to discover truly novel therapeutic opportunities. Understanding these mechanisms also allows us to resolve clinical heterogeneity in drug development. Taken together, this unique process empowers us to discover and develop the next generation of cancer therapies with unprecedented speed and precision.

Mine

Select

Acquire

Amplify

Partner

Leadership

Our multidisciplinary team includes world-class experts from fields ranging from mathematics and AI to systems biology, all guided by deep clinical development experience. The combined expertise enables us to improve and accelerate the discovery and development of novel therapeutics.

SPYRO MOUSSES, PHD

Chief Executive Officer

SPYRO MOUSSES, PHD

Chief Executive Officer

Dr. Mousses is widely recognized as a leading scientist in the application of genomics, systems biology, and machine learning to improve and accelerate cancer drug discovery and development. He has published more than 60 patents, scientific articles, and book chapters. He served as Director of the Pharmaceutical Genomics Division at the Translational Genomics Research Institute (TGen), where he led 8 laboratories to develop more than 30 programs and collaborated with pharmaceutical partners to accelerate cancer drug development. Prior to that, he served as Staff Scientist at the National Human Genome Research Institute (NHGRI), NIH, leading a program in cancer genome scanning and high throughput technology.

As a successful entrepreneur, Dr. Mousses has previously founded several biotech and IT companies, including Systems Medicine (acquired by Cell Therapeutics), MedTrust Online (acquired by Annai Systems), and Systems Imagination, which offers advanced cognitive computing technology to translate big data into biomedical insights.

Dr. Mousses received his PhD in Molecular Pathogenesis and Genetics of Cancer from the University of Toronto. He can be reached at spyro@systemsoncology.com.

Daniel D. Von Hoff, MD, FACP

Chief Clinical Strategist

Daniel D. Von Hoff, MD, FACP

Chief Clinical Strategist

Dr. Von Hoff has been instrumental in the development and approval of many life-saving cancer therapies including gemcitabine, fludarabine, paclitaxel, docetaxel, topotecan, irinotecan, mitoxantrone,vismodegib, nab-paclitaxel and others. He is currently Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Professor of Medicine at the Mayo Clinic, and the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at Honor Health Research Institute.

Dr. Von Hoff is a former member of the FDA’s Oncology Drug Advisory Committee (ODAC) and served on President Bush’s National Cancer Advisory Board. He was previously the Director of the Arizona Cancer Center and former president of the American Association of Cancer Research (AACR). He is a past member of the Board of Scientific Advisors of the National Cancer Institute, as well as a former board member of the American Society of Clinical Oncology (ASCO). Dr. Von Hoff co-founded ILEX Oncology, Inc. in 1993, which was later acquired by Genzyme Corp. in 2004 for $1 billion.

Dr. Von Hoff has published more than 730 papers, 141 book chapters and over 1165 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from ASCO for his outstanding contributions to cancer research leading to significant improvement in patient care. He has also edited the Cancer Chemotherapy Handbook and has had seats on the editorial board of 12 scientific journals, including the founding Editor-in-Chief of Molecular Cancer Therapeutics. Dr. Von Hoff also currently is the Team Leader for the Stand Up to Cancer (SU2C Sponsored) Dream Team focused on developing new agents targeting pancreatic cancer. He can be reached at dvh@systemsoncology.com.

GAVIN BOGLE, JD, MBA, MS

CHIEF Business and LEGAL OFFICER

GAVIN BOGLE, JD, MBA, MS

CHIEF Business and LEGAL OFFICER

Gavin has more than 20 years of global licensing and legal experience across sectors with an emphasis on cross-border business and intellectual property strategy issues. His experience includes corporate transactions, such as acquisitions, financings, licensing and divestitures, managing intellectual property holdings and devising intellectual property strategies. Gavin is a US patent attorney and a Canadian trademark agent. He has significant experience in life sciences law and licensing, including pharmaceutical, biotechnology, and nutritional supplement matters. Gavin has a JD, an MBA and an MS.

Gavin was General Counsel at Iovate, a mid-sized private Canadian company; Patent Counsel at Wyeth Pharmaceuticals in Cambridge MA; Senior Patent Attorney at Genetics Institute in Cambridge MA; and a patent attorney at a major New York IP firm. Gavin also held a clerkship at the Tax Court of Canada. He can be reached at gavin@systemsoncology.com.

CHRIS YOO, PHD

CHIEF TECHNOLOGY OFFICER

CHRIS YOO, PHD

CHIEF TECHNOLOGY OFFICER

Dr. Yoo has over 20 years of experience in advancing cutting-edge biomedical information technology. He co-founded Systems Imagination, Inc., which offers advanced cognitive computing technology to translate big data into valuable insights. Dr. Yoo was instrumental at IBM as Head of Strategy and Planning in the Information Based Medicine group, where he developed initiatives to target the growing field of personalized medicine. He also held other leadership positions at IT and life sciences companies including Cisco, Oracle, and Applied Biosystems.

As a serial entrepreneur, Dr. Yoo continues to create partnerships that accelerate the adoption of personalized medicine through genomics and cognitive computing.

Dr. Yoo received his PhD in Cell and Molecular Biology from Yale University, and completed his postdoctoral fellowship at UC Berkeley. He can be reached at chris@systemsoncology.com.

JEFF Kiefer, PhD

SENIOR VICE PRESIDENT, Discovery Research

JEFF Kiefer, PhD

SENIOR VICE PRESIDENT, Discovery Research

Dr. Kiefer is an accomplished scientist spanning the intersection of cancer biology and genomic technologies. Prior to joining Systems Oncology, he spent 14 years at the Translational Genomics Research Institute (TGen) beginning as a postdoctoral researcher and progressing to the level of Research Associate Investigator. During his time at TGen, he was deeply embedded in numerous major research initiatives involving internal programs and collaborations with industry partners. His multidisciplinary research talents in the areas of cancer biology, systems biology, informatics, and knowledge mining were leveraged to support investigators across the institute and across therapeutic areas. Dr. Kiefer was instrumental in developing interpretation systems, rules and methods for the development of devices to enable multiple precision medicine initiatives involving interactions with the FDA.

Dr. Kiefer received his PhD from the University of Texas Graduate School of Biomedical Sciences and MD Anderson Cancer Center in Houston, Texas. He can be reached at jeff@systemsoncology.com.

ELIZABETH BRUCKHIMER, PHD

Drug Development Advisor

ELIZABETH BRUCKHIMER, PHD

Drug Development Advisor

Dr. Bruckheimer is a Drug Development Advisor at Systems Oncology, as well as Vice President of Drug Development at Cancer Prevention Pharmaceuticals (CPP). Her professional career spans 20 years in oncology research, biotech/ pharmaceutical industry, and contract research organizations. In those endeavors, she led cross-functional preclinical and translational drug development programs, laboratory and organizational operations, project management, and business development activities. Prior to joining CPP, she served as Vice President of Scientific Operations at Champions Oncology leading development of its TumorGraft™ platform and oversaw all scientific operations and project management for Champions’ Translational Oncology Solutions division. Prior to that, Dr. Bruckheimer served as Associate Director and Manager at Systems Medicine, LLC., Senior Scientist at MedImmune, Inc., and Scientist II at Targeted Genetics Corporation where she led the pre-clinical and translational research programs and supported business development opportunities for these organizations. Her expertise and research interests include translational research, oncology drug development, and personalized medicine.

Dr. Bruckheimer received her PhD from the University of Texas Graduate School of Biomedical Sciences and MD Anderson Cancer Center in Houston, Texas. She can be reached at beth@systemsoncology.com.

Chris Brown, PhD, MBA

Vice President, Academic Partnerships

Chris Brown, PhD, MBA

Vice President, Academic Partnerships

Dr. Brown is an entrepreneur and scientist with significant experience in both science and business. He has worked in an academic environment, launched an entrepreneurial life sciences business and worked in a variety of roles at a large fortune 500-sized company.

Dr. Brown has a breadth of research experience in cancer genetics, virology and microbiology. He has investigated molecular aspects of cancer at Mount Sinai Hospital in Toronto and host-virus interactions/programmed cell death at Rutgers University. Dr. Brown started his own firm providing targeted quantitative immuno-detection designs, tools and methods.

Dr. Brown received his PhD from the University of New Brunswick, and an MBA from the University of Victoria. He can be reached at cbrown@systemsoncology.com.

TED TARASOW, PHD

DRUG DEVELOPMENT ADVISOR

TED TARASOW, PHD

DRUG DEVELOPMENT ADVISOR

Dr. Tarasow is an accomplished R&D executive and entrepreneur with more than 24 years of experience in both drug and diagnostic development. He has built and led successful multidisciplinary teams to develop innovative drug discovery technologies, optimize lead compounds, and scale up and transfer synthetic processes for cGMP production and first in human clinical trials. In addition, he has developed novel diagnostic platforms and products, and implemented those products in clinical laboratories.

Dr. Tarasow was a founder of Vanquish Oncology, Invenux Pharmaceuticals, and Transverse Medical. He has also served in executive or leadership roles at HealthTell, Tethys Biosciences, Lawrence Livermore National Laboratory, and NeXstar Pharmaceuticals, as well as on the Scientific Advisory Boards for Systems Oncology and AccelaPure Corporation.

Dr. Tarasow received his PhD in Organic Chemistry from The Scripps Research Institute and his BS in Chemistry from the California Polytechnic State University, San Luis Obispo (Summa Cum Laude). He has published more than 25 scientific articles and has received 8 issued US patents. He can be reached at ted@systemsoncology.com.

DAVID AZORSA, PHD

Director of Biological Therapeutics

DAVID AZORSA, PHD

Director of Biological Therapeutics

Dr. Azorsa is an accomplished scientist with over 20 years of experience in cancer research. He was previously a Senior Scientist in the Institute of Molecular Medicine at Phoenix Children’s Hospital and a Research Associate Professor in the Department of Child Health at the University of Arizona College of Medicine – Phoenix. He also headed the Biological Therapeutics Laboratory at the Translational Genomics Research Institute (TGEN). Dr. Azorsa has authored over 45 papers and has expertise in cellular and molecular biology, antibody development, functional genomics screening, drug screening, and assay development.

Dr. Azorsa received his PhD in Pharmacology and Molecular Sciences from the Johns Hopkins School of Medicine, and completed his postdoctoral fellowship at the INSERM U.311 in Strasbourg, France and the National Human Genome Research Institute at the NIH. He can be reached at dazorsa@systemsoncology.com.

Ramon Moreno, PhD

Scientific Project Manager

Ramon Moreno, PhD

Scientific Project Manager

Dr. Moreno is an accomplished scientist with over a decade of experience in drug discovery and regulatory affairs. Before joining Systems Oncology, he was a project manager and consultant at Resolute Therapeutics. Prior to that, he was Head of Biology at Asinex Corporation where he took an active role expanding its R&D portfolio.

Dr. Moreno received his PhD in Experimental and Molecular Biology from the University of Alicante, Spain, and completed his postdoctoral fellowship at Wake Forest University School of Medicine. He can be reached at ramon@systemsoncology.com

LEE Matricaria

Senior Vice President, Business Development

LEE Matricaria

Senior Vice President, Business Development

Lee has over 25 years of experience in the healthcare industry. He is a successful entrepreneur, having founded, acquired and run multiple companies; including Data Management, Inc. (acquired by MedData), On Point Technology, GrandStay Hospitality and Lakeshore Capital Partners.

Prior to co-founding Lakeshore Capital Partners, Lee spent 12 years at St. Jude Medical. In his most recent role as a Field Clinical Engineer, his responsibilities included designing, implementing, and managing clinical trials for next-generation Cardiac Rhythm Management products, including implantable cardioverter defibrillators (ICD), cardiac pacemakers, and delivery tools.

Lee is a named author on multiple scientific papers and is a graduate of Marquette University. He can be reached at lee@systemsoncology.com.

ANDREW Matricaria, MBA

Chief Financial Officer

ANDREW Matricaria, MBA

Chief Financial Officer

Andrew has 20 years of private equity and healthcare industry experience. As Managing Partner of Lakeshore Capital Partners, Andrew is responsible for evaluating potential investment opportunities, structuring and executing transactions and portfolio company oversight. In his role at Lakeshore, Andrew also provides financial consulting and executive-level management services.

Prior to founding Lakeshore Capital Partners, Andrew worked in brand management at Amgen. While at Amgen, he took on increasing levels of responsibility in the sales and marketing organization. In his most recent role, he directed the strategic planning and operations function for a groundbreaking oncology product launch.

Previously, Andrew worked as an investment banking analyst for Credit Suisse First Boston, where he focused on mergers and acquisitions advisory and debt and equity financings.

Andrew holds a BA from the University of Michigan and an MBA from The Fuqua School of Business at Duke University, with a concentration in Health Sector Management. He can be reached at andrew@systemsoncology.com.

KATY MARHENKE

Director of Operations

KATY MARHENKE

Director of Operations

Katy is the Director of Operations at Systems Oncology. Her key responsibilities include staff, facilities, and document management and oversight. She also supports business development, coordinates corporate meetings and conference calls, and arranges travel and conference attendance. In addition, Katy supports all discovery research efforts including target identification and validation, as well as facilitating contact with external investigators.

Katy received her BS in Molecular Genetics from The Ohio State University. She is currently working towards her MS in Biomedical Informatics from Arizona State University. She can be reached at katy@systemsoncology.com.

TERESA NIU, MA, MBA

Director, Marketing and Business Development

TERESA NIU, MA, MBA

Director, Marketing and Business Development

Teresa has over a decade of experience in the healthcare industry across the US, China, and Taiwan. Her experience includes oncology research, professional and consumer marketing, and public relations.

Teresa started her career as a researcher. At Genentech, she generated over 60 antibodies as drug candidates, several of which are near to market, and TECENTRIQ ® , the first anti-PDL1 cancer immunotherapy approved by the FDA. On the business side, she held professional marketing roles at Novartis Oncology and Bristol-Myers Squibb before joining Ogilvy Public Relations. While at Ogilvy Shanghai office, she led a team of medical/media managers to develop communication strategies for product launch and disease awareness; and received the Award for Exemplary Service from the Fuqua School of Business for strengthening the Fuqua brand in China and Taiwan, granted annually to only 2 alumni worldwide. Her clients included Pfizer, Bristol-Myers Squibb, Roche, Eli Lilly, Sanofi, GlaxoSmithKline, Baxter, and Takeda Millennium.

Teresa holds a BS in Life Science from National Yang Ming University in Taiwan, an MA in Molecular Genetics & Microbiology from the University of Texas at Austin, and an MBA from Duke University – The Fuqua School of Business, with a concentration in Health Sector Management. She can be reached at teresa@systemsoncology.com.

DEVIN SIMON, MS

Director of External Innovation

DEVIN SIMON, MS

Director of External Innovation

Devin is the Director of External Innovation at Systems Oncology. His primary responsibility is to foster relationships and manage communication with research universities/institutes, and to explore and facilitate IP in-licensing opportunities. He also supports marketing operations including web presence, market research, competitive analysis, as well as sponsorships and conference attendance.

Devin received his BS degree at The Ohio State University where he studied personal finance, and his MS in Marketing from the University of Alabama. He can be reached at devin@systemsoncology.com.

James Silver, HBA, LLB, LLM

Licensing and Technology Transactions Advisor

James Silver, HBA, LLB, LLM

Licensing and Technology Transactions Advisor

James is involved in Systems Oncology’s legal, licensing, and transactional matters. He has a background in corporate law, with a particular focus on serving companies in the pharmaceutical, biotechnology, and healthcare sectors.

James graduated from Osgoode Hall Law School, having previously attended City University of London, and the University of Toronto. While in law school, James won several awards for his studies in corporate and commercial law.

In his spare time, James serves on the board of a company involved in neurological therapeutics, volunteers with the International Society for Pediatric Innovation, and is training to become a pilot. He can be reached at james@systemsoncology.com.

The board

RONALD Matricaria

CHAIRMAN OF THE BOARD

RONALD Matricaria

CHAIRMAN OF THE BOARD

Ron has had a distinguished career for the past five decades in the healthcare industry. From 1993 to 2002, he led St. Jude Medical, Inc. in roles of President, CEO, and Chairman. Prior to that, he spent 23 years at Eli Lilly and Company, serving in various roles including President of its pharmaceutical division in North America, Lilly International, and its medical device division. In addition, he served on the board of numerous public and private companies, including Home Depot, Life Technology, Kinetic Concepts, Phoenix Children’s Hospitals, as well as many others.

Ron is currently Chairman of the Board for Systems Oncology and Orthofix International N.V. He is also a Limited Partner at Lakeshore Capital Partners, LLC.

Ron holds a BS degree from Massachusetts College of Pharmacy, and was awarded an honorary Doctor degree in Pharmacy. He also earned a Life Time Achievement award for his significant contributions to the healthcare industry.

SPYRO MOUSSES, PHD

Chief Executive Officer

SPYRO MOUSSES, PHD

Chief Executive Officer

Dr. Mousses is widely recognized as a leading scientist in the application of genomics, systems biology, and machine learning to improve and accelerate cancer drug discovery and development. He has published more than 60 patents, scientific articles, and book chapters. He served as Director of the Pharmaceutical Genomics Division at the Translational Genomics Research Institute (TGen), where he led 8 laboratories to develop more than 30 programs and collaborated with pharmaceutical partners to accelerate cancer drug development. Prior to that, he served as Staff Scientist at the National Human Genome Research Institute (NHGRI), NIH, leading a program in cancer genome scanning and high throughput technology.

As a successful entrepreneur, Dr. Mousses has previously founded several biotech and IT companies, including Systems Medicine (acquired by Cell Therapeutics), MedTrust Online (acquired by Annai Systems), and Systems Imagination, which offers advanced cognitive computing technology to translate big data into biomedical insights.

Dr. Mousses received his PhD in Molecular Pathogenesis and Genetics of Cancer from the University of Toronto. He can be reached at spyro@systemsoncology.com.

Daniel D. Von Hoff, MD, FACP

Chief Clinical Strategist

Daniel D. Von Hoff, MD, FACP

Chief Clinical Strategist

Dr. Von Hoff has been instrumental in the development and approval of many life-saving cancer therapies including gemcitabine, fludarabine, paclitaxel, docetaxel, topotecan, irinotecan, mitoxantrone,vismodegib, nab-paclitaxel and others. He is currently Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen), Professor of Medicine at the Mayo Clinic, and the Virginia G. Piper Distinguished Chair for Innovative Cancer Research at Honor Health Research Institute.

Dr. Von Hoff is a former member of the FDA’s Oncology Drug Advisory Committee (ODAC) and served on President Bush’s National Cancer Advisory Board. He was previously the Director of the Arizona Cancer Center and former president of the American Association of Cancer Research (AACR). He is a past member of the Board of Scientific Advisors of the National Cancer Institute, as well as a former board member of the American Society of Clinical Oncology (ASCO). Dr. Von Hoff co-founded ILEX Oncology, Inc. in 1993, which was later acquired by Genzyme Corp. in 2004 for $1 billion.

Dr. Von Hoff has published more than 730 papers, 141 book chapters and over 1165 abstracts. Dr. Von Hoff received the 2010 David A. Karnofsky Memorial Award from ASCO for his outstanding contributions to cancer research leading to significant improvement in patient care. He has also edited the Cancer Chemotherapy Handbook and has had seats on the editorial board of 12 scientific journals, including the founding Editor-in-Chief of Molecular Cancer Therapeutics. Dr. Von Hoff also currently is the Team Leader for the Stand Up to Cancer (SU2C Sponsored) Dream Team focused on developing new agents targeting pancreatic cancer. He can be reached at dvh@systemsoncology.com.

GAVIN BOGLE, JD, MBA, MS

CHIEF Business and LEGAL OFFICER

GAVIN BOGLE, JD, MBA, MS

CHIEF Business and LEGAL OFFICER

Gavin has more than 20 years of global licensing and legal experience across sectors with an emphasis on cross-border business and intellectual property strategy issues. His experience includes corporate transactions, such as acquisitions, financings, licensing and divestitures, managing intellectual property holdings and devising intellectual property strategies. Gavin is a US patent attorney and a Canadian trademark agent. He has significant experience in life sciences law and licensing, including pharmaceutical, biotechnology, and nutritional supplement matters. Gavin has a JD, an MBA and an MS.

Gavin was General Counsel at Iovate, a mid-sized private Canadian company; Patent Counsel at Wyeth Pharmaceuticals in Cambridge MA; Senior Patent Attorney at Genetics Institute in Cambridge MA; and a patent attorney at a major New York IP firm. Gavin also held a clerkship at the Tax Court of Canada. He can be reached at gavin@systemsoncology.com.

CHRIS YOO, PHD

CHIEF TECHNOLOGY OFFICER

CHRIS YOO, PHD

CHIEF TECHNOLOGY OFFICER

Dr. Yoo has over 20 years of experience in advancing cutting-edge biomedical information technology. He co-founded Systems Imagination, Inc., which offers advanced cognitive computing technology to translate big data into valuable insights. Dr. Yoo was instrumental at IBM as Head of Strategy and Planning in the Information Based Medicine group, where he developed initiatives to target the growing field of personalized medicine. He also held other leadership positions at IT and life sciences companies including Cisco, Oracle, and Applied Biosystems.

As a serial entrepreneur, Dr. Yoo continues to create partnerships that accelerate the adoption of personalized medicine through genomics and cognitive computing.

Dr. Yoo received his PhD in Cell and Molecular Biology from Yale University, and completed his postdoctoral fellowship at UC Berkeley. He can be reached at chris@systemsoncology.com.

ALEX LUKIANOV

BOARD Director

ALEX LUKIANOV

BOARD Director

Alex is Chairman and CEO of Tissue Differentiation intelligence (TDi). He is a serial entrepreneur and immediate past Chairman and CEO of NuVasive, Inc. (de facto founder). He has over 35 years of medical technology industry experience, serving as a senior executive at Medtronic Sofamor Danek, BackCare Group, Smith and Nephew Orthopedics, and a Meadox/Stryker joint venture. He is a long standing orthopedic industry expert, and has received multiple achievement awards in entrepreneurship and leadership, as well as many public appearances at conferences, panels, TV, media, and in Washington, DC.

Alex served on a variety of public, private and not for profit boards including California Health Institute, BIOCOM, Medical Device & Manufacturers Association, Volcano, etc. Currently, he is serving on the public company board of Orthofix, several private and not for profit boards including Chairman and CEO (co-founder) of TDi, Systems Oncology, OnPoint, Holy Trinity Seminary, Chairman of St Photios Orthodox Theological Seminary, and Chairman and CEO of Patriarch Tikhon Russian-American Music Institute.

Alex directs his focus largely on developing new businesses, investments, and proliferation of the arts. He studied at Rutgers, The State University of New Jersey.

KIERAN GALLAHUE

BOARD Director

KIERAN GALLAHUE

BOARD Director

Kieran is the former chairman and chief executive officer of CareFusion (NYSE: CFN) from 2011 until its acquisition by Becton Dickinson (NYSE: BDX) in 2015 for $12.3 billion.

Kieran is currently a director on the boards of Edwards Lifesciences Corp. (NYSE: EW), Intersect ENT (NASDAQ: XENT), Nucleus Biologics and Systems Oncology and is a member of Qualcomm Life’s advisory board. Prior, Kieran served on the Executive Committee of The Advanced Medical Technology Association (AdvaMed), a trade association representing 80% of medical technology firms in the US. He has served as both the Chairman of the International Business Committee and as AdvaMed’s Treasurer. In addition, he served on the board of directors of Volcano Corp. (NASDAQ: VOLC), a developer of products for interventional cardiology and image guided therapy, from 2007 until its acquisition by Philips in 2015 for $1.3 billion.

Previously, Kieran served as President, CEO and a Director of ResMed, a medical device firm serving the sleep disordered breathing and respiratory markets. Prior to that, he held positions of increasing responsibility at Nanogen, Instrumentation Laboratory, The Procter & Gamble Company and GE.

Kieran holds a bachelor’s degree in Economics from Rutgers University and an MBA from Harvard Business School.

Scientific Advisory Board

PAUL HERGENROTHER, PHD

Professor of Chemistry, UIUC

PAUL HERGENROTHER, PHD

Professor of Chemistry, UIUC

Professor Hergenrother’s research focuses on the design and evaluation of novel small molecules for the treatment of intractable diseases. He is the co-founder and Chief Scientific Officer of Vanquish Oncology, and an anticancer compound discovered by his lab is being evaluated in clinical trials in cancer patients.

Professor Hergenrother joined the faculty at the University of Illinois in 2001. At the University, he is the Leader of the Theme “Anticancer Discovery from Pets to People” at the Institute for Genomic Biology, and is the Director of the NIH Chemistry-Biology Interface Training Grant. He was the recipient of the 2016 Innovation Transfer Award from the University, was named as an American Cancer Society Research Scholar, and was named by Technology Review magazine as one of the top innovators under the age of 35. More recently, he was named as the recipient of the 2016 UCB-Ehrlich Award for Excellence in Medicinal Chemistry, a 2017 ACS Arthur C. Cope Scholar Award, and the 2018 ACS Sosnovsky Award for Cancer Research.

Professor Hergenrother received his PhD in Chemistry from the University of Texas at Austin, and completed an American Cancer Society Postdoctoral Fellowship at Harvard University.

DAVID BOOTHMAN, PHD

Professor of Biochem. & Molecular Biology, Indiana Univ.

DAVID BOOTHMAN, PHD

Professor of Biochem. & Molecular Biology, Indiana Univ.

Dr. Boothman is Professor of Biochemistry and Molecular Biology at Indiana University School of Medicine. He is a senior leader within the Indiana University Melvin and Bren Simon Cancer Center, serving as Associate Director for Translational Research and co-Director of the Experimental and Developmental Therapeutics (EDT) research program. Dr. Boothman is also the Sid and Lois Eskenazi Chair of Oncology. He is an elected representative for FASEB and is president-elect of the Society of Experimental Biology (SEBM). His current research projects include: (a) Use of NQO1 bioactivatable drugs for therapy of human solid NQO1+ cancers alone and with ionizing radiation (IR); (b) Use of NQO1 bioactivatable drugs to promote the tumor-selective use of DNA repair inhibitors, such as PARP inhibitors; and (c) Elucidating the roles of RNA termination factors in R-loop resolution, DSB repair defects, genetic instability and cancer vulnerabilities. His research is supported by four current NIH/NCI R01 awards, and an NIH U01 to support his radiation oncology research.

Dr. Boothman received his PhD in Microbiology and Immunology from the University of Miami Medical School, and completed his postdoctoral fellowship at Dana-Farber Cancer Institute of Harvard Medical School.

Stephen Munk, PhD

Deputy Director, Biodesign Institute at ASU

Stephen Munk, PhD

Deputy Director, Biodesign Institute at ASU

Dr. Munk has extensive experience in drug discovery, development, and manufacturing. Before joining the Biodesign Institute at ASU in 2017, he was the CEO and President of Ash Stevens Inc., a full service Active Pharmaceutical Ingredient (API) development and manufacturing organization. Under his leadership, Ash Stevens received 12 FDA approvals to manufacture innovator drug substances including 6 oncology drugs. Ash Stevens won 6 NIH research contracts during his tenure. Prior to that, he worked at Allergan, initially as a medicinal chemist and subsequently, the co-team leader of the adrenergic drug discovery team.

Dr. Munk’s work has been summarized in a number of publications and patents. He is a co-author of the 2016 book – Managing the Drug Discovery Process: How to Make It More Efficient and Cost-Effective. He served as an Adjunct Professor of Chemistry at Wayne State University, as well as on the Steering Committee of the Chemistry in Cancer Research Working Group of the American Association for Cancer Research (CICR-AACR), and the Board of Directors of MichBio (Michigan BIO) affiliate.

Dr. Munk holds a PhD in Organic Synthesis from The University of California at Berkeley and a BS in Chemistry from ASU. He also completed an American Cancer Society Postdoctoral Fellowship at Purdue.

Stephen Gately, PhD

President and CEO, Translational Drug Development (TD2)

Stephen Gately, PhD

President and CEO, Translational Drug Development (TD2)

Dr. Gately is the President and CEO of Translational Drug Development (TD2). Prior to joining TD2, and adjunct Assistant Professor of Medicine at the Northwestern University Feinberg School of Medicine. Prior to joining TD2, Dr. Gately served as a consultant to Takeda Pharmaceuticals North America, Medical and Scientific Affairs group where he was responsible for the integration of research and regulatory data on portfolio compounds for commercial planning. He was also involved in the scientific due diligence for oncology business development opportunities.

Prior to that, he served as Executive Director of Translational Medicine at NeoPharm, and was in charge of the design and implementation of research to enhance the understanding of existing products and development candidates for optimal positioning.

Prior to joining NeoPharm, Dr. Gately was a Research Assistant Professor at Northwestern University where he focused on developing pharmacologic and endogenous inhibitors of angiogenesis. During this time, he served as a consultant to the Oncology Clinical Research team at Searle/Monsanto (now Pfizer), and was responsible for scientific input on clinical trial designs to rapidly assess the utility of antiangiogenic compounds.

Dr. Gately obtained his PhD from McGill University in the Department of Neurology and Neurosurgery at the Montreal Neurological Institute and Hospital.

OUR partners

Leveraging unique data-driven insights into cancer biology, we collaborate with universities and research institutes worldwide to discover and advance innovative therapeutic agents. We work closely with our academic collaborators to translate scientific insights into smarter clinical development strategies and faster registration paths. Once we have achieved proof of concept, we then leverage our network of leading pharmaceutical companies who partner with us to bring life-saving drugs to market.

We welcome opportunities to collaborate with leading universities and biotech companies to advance innovative cancer therapies. Please email us a non-confidential description of your technology or collaboration opportunity at info@systemsoncology.com.

CAREERS FOR CANCER WARRIORS

At Systems Oncology, we provide a collaborative environment, excellent benefits, and exciting training opportunities for professionals to thrive and grow. Apply today if you are interested in the development of innovative cancer therapeutics!

Open positions

Content Development Internship

Content Development Internship

Scottsdale, Arizona

Systems Oncology utilizes advanced technologies to mine big-data to uncover hidden biomedical insights which are leveraged to identify novel targeted approaches and opportunities for cancer therapeutics. We then invest to acquire and advance the most promising experimental therapeutics to achieve proof of concept. Finally, we partner with leading pharmaceutical companies to transform innovative new agents into the next breakthrough cancer therapies.

This program will provide a unique learning opportunity for students to develop both scientific and business development skills. Interns will train with seasoned executives and use state of the art technologies, as they participate in data mining and research to find and evaluate experimental therapeutics with potential to be advanced as new cancer drugs.

Key Responsibilities:

Mining existing datasets and information resources to find experimental therapeutics that are available for licensing.

The opportunity to interact with technology transfer offices at academic institutions and research centers across the country.

Translation of licensing information about experimental treatments to develop a knowledgebase.

Utilizing principles of bioinformatics to help match drug targets and disease pathways to experimental therapeutics.

Participating in a weekly seminar series with esteemed experts from the Phoenix area.

Preferred Education & Experience:

University level or coursework leading towards a Bachelor’s Degree in BMI, Biology, Business, or a closely related field.

Desired Skills, Knowledge & Abilities:

Strong written and verbal skills to communicate with clarity and brevity to other professionals.

A good understanding of molecular biology.

Good organizational and project management skills.

Ability to work collaboratively in a team environment.

Desire to learn and expand knowledge in scientific methods and data analysis.

Ability to quickly learn new processes and tools, business domains and technical applications.

Social Media Internship

Social media Internship

Scottsdale, Arizona

Systems Oncology utilizes advanced technologies to mine big-data to uncover hidden biomedical insights which are leveraged to identify novel targeted approaches and opportunities for cancer therapeutics. We then invest to acquire and advance the most promising experimental therapeutics to achieve proof of concept. Finally, we partner with leading pharmaceutical companies to transform innovative new agents into the next breakthrough cancer therapies.

This program will provide a unique learning opportunity for students to develop social media and marketing skills. The Social Media Intern is responsible for creating and maintaining content for Systems Oncology’s social media platforms. This intern will use strategic research, planning, and monitoring in order to increase brand awareness, improve marketing efforts and promote the distribution of relevant information to community members and the general public.

AI/Machine Learning Researchers

AI/Machine Learning Researchers

Scottsdale, Arizona

Systems Oncology utilizes advanced technologies to mine big-data to uncover hidden biomedical insights which are leveraged to identify novel targeted approaches and opportunities for cancer therapeutics. We then invest to acquire and advance the most promising experimental therapeutics to achieve proof of concept. Finally, we partner with leading pharmaceutical companies to transform innovative new agents into the next breakthrough cancer therapies.

Responsibilities:

The AI/Machine Learning Researchers will be responsible for the design, development and creation of analytical solutions using artificial intelligence methods including neural networks, inference engines, simulations and other mechanisms. They will join an interdisciplinary team of software engineers, computational biologists, bioinformatics analysts, and laboratory scientists to develop new methodologies to rapidly identify novel genotypic and phenotypic factors that may lead to disease, to offer best-in-class tech-enabled services to healthcare & life sciences clients, and to provide better options for disease diagnosis and treatment.

The AI/Machine Learning Researchers will be expected to maintain a high level of professional standards in analysis, algorithm development/enhancement, and GPU and tensor acceleration to support the various initiatives of the organization. Successful candidates will also have excellent written and verbal communication skills to both technical and non-technical audiences.

Requirements:

MS or PhD in Computer/Cognitive Science or Mathematics

4+ years of experience with computational systems, including 1+ year of post-graduate experience

Immunotherapy Project Manager

Immunotherapy Project Manager

Scottsdale, Arizona

Systems Oncology utilizes advanced technologies to mine big-data to uncover hidden biomedical insights which are leveraged to identify novel targeted approaches and opportunities for cancer therapeutics. We then invest to acquire and advance the most promising experimental therapeutics to achieve proof of concept. Finally, we partner with leading pharmaceutical companies to transform innovative new agents into the next breakthrough cancer therapies.

We are seeking an Immunotherapy Project Manager to support project development activities. The Immunotherapy Project Manager will be responsible for the overall coordination of proof-of-concept, proof-of-efficacy preclinical research projects, non-clinical toxicology and Pre-IND activities for our internal projects. The Immunotherapy Project Manager will work daily with all members of a diverse team, collaborating scientists, and contract research organizations (CROs) to prepare study designs, obtain quotes from collaborating scientist and CROs to perform the studies, and manages the study from initiation to report generation. The Immunotherapy Project Manager will also assist in tracking project progress, data interpretation, reporting, and compilation of results for internal and external presentations.

The successful candidate must be self-motivated and objective-driven. An in-depth understanding of cancer biology, oncology drug development, excellent communication skills, and proficiency with project tracking and communication tools are essential. The position requires an advanced understanding of, and proficiency with experimental procedures routinely met in a pharmacology laboratory and drug development.

The Project Manager position offers fulfilling interactions both with internal scientists and external investigators, and a variety of opportunities for learning and advancement.

Key Skills and Responsibilities:

Detail-oriented proficiency in the design and management of in vitro studies as well as in vivo proof of concept and non-clinical toxicology studies used in a drug development setting

Strong proficiency with software tools including Microsoft Office, GraphPad Prism, and Project management tools such as Trello and Omniplan

Superior organizational skills and attention to detail necessary to maintain project records and cross-functional area collaborations

Exceptional verbal and written communication skills. Must be able to establish effective two-way communication with CROs, collaborators and team members regarding scientific needs and deadlines

Dedication to project success in a fast-paced scientific and business driven environment

Requirements:

Master’s or PhD in Biological Science, preferably in cancer biology or a related field

1-3 years minimum experience in pharmaceutical drug development

Knowledge of cancer drug development including in vivo proof of concept studies, non-clinical toxicology, and the IND process

To Apply:

Please submit your CV/cover letter to info@systemsoncology.com, and include the job title for which you are applying in the subject line.

All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, disability or protected veteran status.

SOFTWARE ENGINEER

SOFTWARE ENGINEER

Scottsdale, Arizona

Systems Oncology utilizes advanced technologies to mine big-data to uncover hidden biomedical insights which are leveraged to identify novel targeted approaches and opportunities for cancer therapeutics. We then invest to acquire and advance the most promising experimental therapeutics to achieve proof of concept. Finally, we partner with leading pharmaceutical companies to transform innovative new agents into the next breakthrough cancer therapies.

Responsibilities:

We are seeking a Software Engineer (SE) to join our dynamic team. The SE will be responsible for requirements analysis, software design and development with a focus on algorithms, data management and representation and AI, with some focus in bioinformatics.

The SE will work with a team of software engineers, computational biologists, bioinformatics analysts, and laboratory scientists to develop new methodologies to rapidly identify novel genotypic and phenotypic factors that may lead to disease, to offer best-in-class tech-enabled services to healthcare & life sciences clients, and to provide better options for disease diagnosis and treatment. The SE will be expected to maintain a high level of professional standards in analysis and development coding to support the various initiatives of the organization. The successful candidate will have a demonstrated ability to work in a fast-paced environment with a focus on delivery of high speed and high availability systems and solutions.

SYSTEMS BIOLOGIST

SYSTEMS BIOLOGIST

Scottsdale, Arizona

Systems Oncology utilizes advanced technologies to mine big-data to uncover hidden biomedical insights which are leveraged to identify novel targeted approaches and opportunities for cancer therapeutics. We then invest to acquire and advance the most promising experimental therapeutics to achieve proof of concept. Finally, we partner with leading pharmaceutical companies to transform innovative new agents into the next breakthrough cancer therapies.

We are seeking a Systems Biologist to support discovery research using novel technological platforms, machine learning, and computational modeling. The Systems Biologist will be responsible for the development, testing, and implementation of unique methods and techniques for the analysis of large-scale biomedical data to support drug discovery and development. In this role, the Systems Biologist will work with scientists with diverse backgrounds ranging from basic biological research to information science. The successful candidate is expected to have a working knowledge of cancer biology and drug development.

Key Responsibilities:

Perform computational research to support drug discovery

Support the development of databases, software, and their application in systems biology research

Participate in team-based working environment across multiple scientific disciplines

Dedication to project success in a fast-paced science and business driven environment